|
Researchers at Massachusetts Institute of Technology and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, which could be an alternative to drug-eluting stents in some patients with cardiovascular disease, according to research published in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.
New Jersey radiologist Bruce N. Saffran, MD, who was awarded about $500 million in a 2008 patent infringement case against Boston Scientific, filed suit Monday in the U.S. District Court for the Eastern District of Texas over Abbott's Xience V everolimus-eluting coronary stent.
Cook Medical and Angiotech Pharmaceuticals received CE Mark approval Monday for their polymer-free Zilver PTX drug-eluting peripheral stent to treat blockages in the legs caused by peripheral arterial disease.
Abbott posted its financial results for the second quarter, which ended June 30, showing a 2.6 percent decrease in net earnings--to $1.29 billion from $1.32 billion in the same period last year.
Boston Scientific has received approval from the FDA to market its Taxus Liberte Atom paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for treating small coronary vessels, as small as 2.25 mm in diameter.
|
Abbott has launched its Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease at the European Society of Cardiology (ESC) Congress this week in Barcelona, Spain.
Abbott has received approval from Health Canada for the Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease.
Boston Scientific has reported positive financial earnings for its fiscal 2009 second quarter, which ended June 30. The Natick, Mass.-based medical device company booked a net income of $158 million this quarter, compared with $98 million in the second quarter of 2008.
Abbott has received CE Mark for its next-generation Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The company plans to launch Xience Prime in a varied size matrix, with lengths up to 38 mm, in the third quarter across Europe.
Treating critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty is thwarted by restenosis, the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death and amputation. However, interventional radiologists have found that drug-eluting stents (DES) lessen the rate of repeat procedures to open these small arteries, according to results presented at the Society of Interventional Radiology (SIR) annual meeting in San Diego this week.
|
RSS 
Using an advanced massive-training artificial neural network, computer-aided detection (CAD) scheme, radiologists were able to improve their polyp detection rate and reduce the number of false positives in CT colonography, based on a study presented at the 2009 Radiological Society of North America (RSNA) annual conference in Chicago.
Organizations should act prior to the implementation of the new (Health Insurance Portability and Accountability Act) HIPAA compliance guideline changes for 2010 and consistently monitor their facilities in order to make an easier transition and avoid the extended penalties that are now being proposed, said HIPAA privacy and security consult Grant Peterson during a Jan. 13 Webinar on the guidelines.